Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease
- PMID: 24603212
- DOI: 10.1016/j.drudis.2014.02.006
Mechanisms of synaptic dysfunction and excitotoxicity in Huntington's disease
Abstract
Huntington's disease (HD) is an inherited neurodegenerative disorder of movement, mood and cognition, caused by a polyglutamine expansion in the huntingtin (Htt) protein. Genetic mouse models of HD, along with improved imaging techniques in humans at risk of, or affected by, HD, have advanced understanding of the cellular and/or molecular mechanisms underlying its pathogenesis. The striatum begins to degenerate before other brain areas, and altered activity at corticostriatal synapses contributes to an imbalance in survival versus death signaling pathways in this brain region. Striatal projection neurons of the indirect pathway are most vulnerable, and their dysfunction contributes to motor symptoms at early stages of the disease. Mutant Htt expression changes striatal excitatory synaptic activity by decreasing glutamate uptake and increasing signaling at N-methyl-d-aspartate receptors (NMDAR). A variety of studies indicate that reduced brain-derived neurotrophic factor (BDNF) transcription, transport and signaling contribute importantly to striatal neuronal dysfunction and degeneration in HD. Striatal dopamine and endocannabinoid signaling are also altered and progressively become dysfunctional. Changes at striatal neurons vary with the stage of disease and clinical symptoms. Therapeutics targeting multiple neurotransmitter signaling systems could support physiological synaptic function and delay disease onset.
Copyright © 2014 Elsevier Ltd. All rights reserved.
Similar articles
-
Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.Neurobiol Dis. 2012 Oct;48(1):40-51. doi: 10.1016/j.nbd.2012.05.013. Epub 2012 Jun 2. Neurobiol Dis. 2012. PMID: 22668780
-
Neuronal vulnerability in mouse models of Huntington's disease: membrane channel protein changes.J Neurosci Res. 2005 Jun 1;80(5):634-45. doi: 10.1002/jnr.20492. J Neurosci Res. 2005. PMID: 15880743
-
Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.Neuroscience. 2013 Oct 22;251:66-74. doi: 10.1016/j.neuroscience.2012.05.043. Epub 2012 May 24. Neuroscience. 2013. PMID: 22633949 Review.
-
N-methyl-D-aspartate (NMDA) receptor function and excitotoxicity in Huntington's disease.Prog Neurobiol. 2007 Apr;81(5-6):272-93. doi: 10.1016/j.pneurobio.2006.11.003. Epub 2006 Dec 22. Prog Neurobiol. 2007. PMID: 17188796 Review.
-
Selective neuronal degeneration in Huntington's disease.Curr Top Dev Biol. 2006;75:25-71. doi: 10.1016/S0070-2153(06)75002-5. Curr Top Dev Biol. 2006. PMID: 16984809 Review.
Cited by
-
Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.J Clin Invest. 2019 May 6;129(6):2390-2403. doi: 10.1172/JCI120616. eCollection 2019 May 6. J Clin Invest. 2019. PMID: 31063986 Free PMC article.
-
Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned?Int J Biol Sci. 2014 Sep 10;10(9):1024-38. doi: 10.7150/ijbs.9898. eCollection 2014. Int J Biol Sci. 2014. PMID: 25285035 Free PMC article. Review.
-
Mitochondrial Mechanisms of Neuronal Cell Death: Potential Therapeutics.Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:437-454. doi: 10.1146/annurev-pharmtox-010716-105001. Annu Rev Pharmacol Toxicol. 2017. PMID: 28061689 Free PMC article. Review.
-
VMAT2 Inhibitors in Neuropsychiatric Disorders.CNS Drugs. 2018 Dec;32(12):1131-1144. doi: 10.1007/s40263-018-0580-y. CNS Drugs. 2018. PMID: 30306450 Review.
-
Azadiradione Restores Protein Quality Control and Ameliorates the Disease Pathogenesis in a Mouse Model of Huntington's Disease.Mol Neurobiol. 2018 Aug;55(8):6337-6346. doi: 10.1007/s12035-017-0853-3. Epub 2018 Jan 2. Mol Neurobiol. 2018. PMID: 29294248
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical